Filing Details
- Accession Number:
- 0001765581-20-000107
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-04 19:33:51
- Reporting Period:
- 2020-11-02
- Accepted Time:
- 2020-11-04 19:33:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1232524 | Jazz Pharmaceuticals Plc | JAZZ | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1202769 | L Paul Berns | 5Th Fl, Waterloo Exchange Waterloo Rd Dublin 4 L2 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2020-11-02 | 4,691 | $0.00 | 14,431 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2020-11-04 | 466 | $147.44 | 13,965 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-11-04 | 400 | $149.28 | 13,565 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2020-11-04 | 3,825 | $150.90 | 9,740 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Phantom Stock | Disposition | 2020-11-02 | 4,691 | $0.00 | 4,691 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2020-11-02 | 2020-11-02 | No | 4 | M | Direct |
Footnotes
- On November 2, 2020, the Reporting Person's 4,691 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.04 to $149.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.515 to $151.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
